Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients
The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agen...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2004-07, Vol.40 (11), p.1776-1786 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1786 |
|---|---|
| container_issue | 11 |
| container_start_page | 1776 |
| container_title | European journal of cancer (1990) |
| container_volume | 40 |
| creator | Shomura, Hiroki Shichijo, Shigeki Komatsu, Nobukazu Matsueda, Satoko Mine, Takashi Rikimaru, Toru Sato, Yuji Todo, Satoru Itoh, Kyogo |
| description | The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24
+ NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54–62, 124–132 and 800–809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy. |
| doi_str_mv | 10.1016/j.ejca.2004.04.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66701300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804904003077</els_id><sourcerecordid>66701300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-8c00e3bc3b85e8c4a9aa4ddea9e3980279ed1aec69432920fbc481855203d273</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhYMoTtv6Ai4kG90M1d6k_hJw0wyOM9DgZvYhldzqSVOVlEnVyDyU72jKbpidEMjP_c7N5RxCPjLYMWDN19MOT0bvOEC1WxeUr8iGiVYWIGr-mmxA1rIQUMkr8i6lEwC0ooK35IrVvGaskRvy596in13vjJ5d8DT0FCdnMY56oMcYfs-PtNdmDpFGNDjlQ5Gr7gktnfI1o2mthKN3Kb91z7QLWWNwGJZBR6q9pY_LGGLu58Zx8ZjxNAWfstB5enfYF3te0Wvqgy9S_nb4J6bD4o_UaG8w0ikPl8dM78mbXg8JP1z2LXm4_f5wc1ccfv64v9kfClMKPhfCAGDZmbITNQpTaal1ZS1qiaUUwFuJlmk0jaxKLjn0nakEE3XNobS8Lbfky7ntFMOvBdOsRpfWobTHsCTVNC2wMvu9JfwMmhhSitirKbpRx2fFQK0ZqZNaM1JrRmpdUGbRp0v3pRvRvkguoWTg8wXQyeihj9kEl164BppKtFXmvp05zFY8OYwqmWyTQetyIrOywf1vjr8qa7Ky</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66701300</pqid></control><display><type>article</type><title>Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Shomura, Hiroki ; Shichijo, Shigeki ; Komatsu, Nobukazu ; Matsueda, Satoko ; Mine, Takashi ; Rikimaru, Toru ; Sato, Yuji ; Todo, Satoru ; Itoh, Kyogo</creator><creatorcontrib>Shomura, Hiroki ; Shichijo, Shigeki ; Komatsu, Nobukazu ; Matsueda, Satoko ; Mine, Takashi ; Rikimaru, Toru ; Sato, Yuji ; Todo, Satoru ; Itoh, Kyogo</creatorcontrib><description>The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24
+ NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54–62, 124–132 and 800–809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2004.04.003</identifier><identifier>PMID: 15251169</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antibody Formation ; Biological and medical sciences ; Cancer vaccine ; Carcinoma, Non-Small-Cell Lung - immunology ; CTL ; EGFR ; Enzyme-Linked Immunosorbent Assay ; HLA-A Antigens - immunology ; HLA-A24 Antigen ; Humans ; Immunoglobulin G - metabolism ; Interferon-gamma - metabolism ; Lung cancer ; Lung Neoplasms - immunology ; Medical sciences ; Peptides ; Peptides - analysis ; Pharmacology. Drug treatments ; Pneumology ; Receptor, Epidermal Growth Factor - chemistry ; T-Lymphocytes, Cytotoxic - immunology ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>European journal of cancer (1990), 2004-07, Vol.40 (11), p.1776-1786</ispartof><rights>2004 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-8c00e3bc3b85e8c4a9aa4ddea9e3980279ed1aec69432920fbc481855203d273</citedby><cites>FETCH-LOGICAL-c382t-8c00e3bc3b85e8c4a9aa4ddea9e3980279ed1aec69432920fbc481855203d273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2004.04.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16064874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15251169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shomura, Hiroki</creatorcontrib><creatorcontrib>Shichijo, Shigeki</creatorcontrib><creatorcontrib>Komatsu, Nobukazu</creatorcontrib><creatorcontrib>Matsueda, Satoko</creatorcontrib><creatorcontrib>Mine, Takashi</creatorcontrib><creatorcontrib>Rikimaru, Toru</creatorcontrib><creatorcontrib>Sato, Yuji</creatorcontrib><creatorcontrib>Todo, Satoru</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><title>Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24
+ NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54–62, 124–132 and 800–809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.</description><subject>Antibody Formation</subject><subject>Biological and medical sciences</subject><subject>Cancer vaccine</subject><subject>Carcinoma, Non-Small-Cell Lung - immunology</subject><subject>CTL</subject><subject>EGFR</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>HLA-A Antigens - immunology</subject><subject>HLA-A24 Antigen</subject><subject>Humans</subject><subject>Immunoglobulin G - metabolism</subject><subject>Interferon-gamma - metabolism</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - immunology</subject><subject>Medical sciences</subject><subject>Peptides</subject><subject>Peptides - analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Receptor, Epidermal Growth Factor - chemistry</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEUhYMoTtv6Ai4kG90M1d6k_hJw0wyOM9DgZvYhldzqSVOVlEnVyDyU72jKbpidEMjP_c7N5RxCPjLYMWDN19MOT0bvOEC1WxeUr8iGiVYWIGr-mmxA1rIQUMkr8i6lEwC0ooK35IrVvGaskRvy596in13vjJ5d8DT0FCdnMY56oMcYfs-PtNdmDpFGNDjlQ5Gr7gktnfI1o2mthKN3Kb91z7QLWWNwGJZBR6q9pY_LGGLu58Zx8ZjxNAWfstB5enfYF3te0Wvqgy9S_nb4J6bD4o_UaG8w0ikPl8dM78mbXg8JP1z2LXm4_f5wc1ccfv64v9kfClMKPhfCAGDZmbITNQpTaal1ZS1qiaUUwFuJlmk0jaxKLjn0nakEE3XNobS8Lbfky7ntFMOvBdOsRpfWobTHsCTVNC2wMvu9JfwMmhhSitirKbpRx2fFQK0ZqZNaM1JrRmpdUGbRp0v3pRvRvkguoWTg8wXQyeihj9kEl164BppKtFXmvp05zFY8OYwqmWyTQetyIrOywf1vjr8qa7Ky</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Shomura, Hiroki</creator><creator>Shichijo, Shigeki</creator><creator>Komatsu, Nobukazu</creator><creator>Matsueda, Satoko</creator><creator>Mine, Takashi</creator><creator>Rikimaru, Toru</creator><creator>Sato, Yuji</creator><creator>Todo, Satoru</creator><creator>Itoh, Kyogo</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients</title><author>Shomura, Hiroki ; Shichijo, Shigeki ; Komatsu, Nobukazu ; Matsueda, Satoko ; Mine, Takashi ; Rikimaru, Toru ; Sato, Yuji ; Todo, Satoru ; Itoh, Kyogo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-8c00e3bc3b85e8c4a9aa4ddea9e3980279ed1aec69432920fbc481855203d273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibody Formation</topic><topic>Biological and medical sciences</topic><topic>Cancer vaccine</topic><topic>Carcinoma, Non-Small-Cell Lung - immunology</topic><topic>CTL</topic><topic>EGFR</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>HLA-A Antigens - immunology</topic><topic>HLA-A24 Antigen</topic><topic>Humans</topic><topic>Immunoglobulin G - metabolism</topic><topic>Interferon-gamma - metabolism</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - immunology</topic><topic>Medical sciences</topic><topic>Peptides</topic><topic>Peptides - analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Receptor, Epidermal Growth Factor - chemistry</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shomura, Hiroki</creatorcontrib><creatorcontrib>Shichijo, Shigeki</creatorcontrib><creatorcontrib>Komatsu, Nobukazu</creatorcontrib><creatorcontrib>Matsueda, Satoko</creatorcontrib><creatorcontrib>Mine, Takashi</creatorcontrib><creatorcontrib>Rikimaru, Toru</creatorcontrib><creatorcontrib>Sato, Yuji</creatorcontrib><creatorcontrib>Todo, Satoru</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shomura, Hiroki</au><au>Shichijo, Shigeki</au><au>Komatsu, Nobukazu</au><au>Matsueda, Satoko</au><au>Mine, Takashi</au><au>Rikimaru, Toru</au><au>Sato, Yuji</au><au>Todo, Satoru</au><au>Itoh, Kyogo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>40</volume><issue>11</issue><spage>1776</spage><epage>1786</epage><pages>1776-1786</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24
+ NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54–62, 124–132 and 800–809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15251169</pmid><doi>10.1016/j.ejca.2004.04.003</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2004-07, Vol.40 (11), p.1776-1786 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66701300 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antibody Formation Biological and medical sciences Cancer vaccine Carcinoma, Non-Small-Cell Lung - immunology CTL EGFR Enzyme-Linked Immunosorbent Assay HLA-A Antigens - immunology HLA-A24 Antigen Humans Immunoglobulin G - metabolism Interferon-gamma - metabolism Lung cancer Lung Neoplasms - immunology Medical sciences Peptides Peptides - analysis Pharmacology. Drug treatments Pneumology Receptor, Epidermal Growth Factor - chemistry T-Lymphocytes, Cytotoxic - immunology Tumors Tumors of the respiratory system and mediastinum |
| title | Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A19%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20epidermal%20growth%20factor%20receptor-derived%20peptides%20recognised%20by%20both%20cellular%20and%20humoral%20immune%20responses%20in%20HLA-A24%20+%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Shomura,%20Hiroki&rft.date=2004-07-01&rft.volume=40&rft.issue=11&rft.spage=1776&rft.epage=1786&rft.pages=1776-1786&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2004.04.003&rft_dat=%3Cproquest_cross%3E66701300%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66701300&rft_id=info:pmid/15251169&rft_els_id=S0959804904003077&rfr_iscdi=true |